Идёт набор NCT06940739

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Фаза I / Фаза II С лечением Unresectable Melanoma Metastatic Melanoma Ocular Melanoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: IOV-3001.
Кому может быть актуально: Состояния в реестре: Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma. Базовые параметры: 18 лет — 70 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Австралия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel

Обзор

A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.

Подробное описание

This study is the first-in-human (FIH) study of IOV-3001. IOV-3001 is an antibody interleukin-2 (IL-2) fusion protein in which a modified form of aldesleukin is incorporated into the antibody palivizumab.

The Phase 1 portion will include 2 parts. Participants will receive IOV-3001 either before the Lifileucel regimen (Part 1) or after Lifileucel instead of aldesleukin (Part 2).

Вмешательства

Биопрепарат IOV-3001
IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.

Первичные конечные точки

Safety and Tolerability [Срок оценки: Up to 30 days]
Recommended Dose for Phase 2 [Срок оценки: Up to 30 days]

Вторичные конечные точки (10)

Pharmacokinetics (PK) profile of IOV-3001 [Срок оценки: Up to 8 days]
Pharmacodynamic (PD) Profile of IOV-3001 [Срок оценки: Up to 8 days]
Antidrug Antibody (ADA) Profile [Срок оценки: Up to 5 years]
Overall Response Rate (ORR) [Срок оценки: Up to 5 years]
Complete Response (CR) rate [Срок оценки: Up to 5 years]
Duration of Response (DOR) [Срок оценки: Up to 5 years]
Disease Control Rate (DCR) [Срок оценки: Up to 5 years]
Progression-Free Survival (PFS) [Срок оценки: Up to 5 years]
Overall Survival (OS) [Срок оценки: Up to 5 years]
In vivo persistence of Lifileucel [Срок оценки: Up to 5 years]

Критерии участия

Критерии включения

Participant must be ≥ 18 years of age at the time of signing the informed consent.
Participant has unresectable or metastatic melanoma.
Participant has melanoma not of uveal/ocular origin and experienced documented radiographic disease progression during systemic therapy with a PD-1/PD-L1 blocking antibody or within 12 weeks after the last dose of the PD-1/PD-L1 blocking antibody. If the tumor is BRAF V600 mutation positive, the participant also received or refused a BRAF inhibitor with or without a MEK inhibitor.

OR Phase 1, Part 1 only: For participants with uveal melanoma, tebentafusp must have been received if available as standard of care (human leukocyte antigen \[HLA\]-A\*02:01 positive participant and approved by local authorities for uveal melanoma) or refused.

Participant has an ECOG performance status of 0 or 1 and, in the investigator's opinion, an estimated life expectancy of > 6 months.
Phase 1, Part 2 only: Following tumor resection for lifileucel generation, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1.
Participant has recovered from all prior anticancer treatment-related AEs

Критерии исключения

Participant has symptomatic untreated brain metastases.
Participant is at an increased risk for systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
Participant has active uveitis that requires active treatment.
Participant has any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease \[SCID\] or AIDS).
Participant has a history of hypersensitivity to any component of the study intervention.
Participant had another primary malignancy within the previous 3 years.
Participants who require systemic steroid therapy 10 mg/day prednisone or another steroid equivalent dose.
Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет